Mapt knockout rat (Cy23)

RESEARCH MODELS Summary These tau knockout rats were created through transcription activator-like effector nuclease (TALEN)-mediated targeting of exon 2 of the rat Mapt gene (Ayers, Lopez et al., 2024). Tau protein was undetectable in the brains of Cy23 rats by western b

APOE C130R (ApoE4)

MUTATIONS APOE 44908684 GRCh38/hg38 rs429358 T C 45411941 GRCh37/hg19 rs429358 T C Exon 4 Coding Strongest known risk factor for AD. Implicated in Aβ and tau pathologies, as well as in multiple other neuronal and non-neuronal functions. C130R Alzheimer's Disea

Notice of Informational Webinar: Implementation Research for Multi-morbidity Management in the Context of Non-communicable Diseases in Low and Middle-Income Countries and US Tribal Populations (R01 Clinical Trial Optional; R61/R33 Clinical Trial Required) (NOT-TW-24-011)

GRANT Friday, November 1, 2024- 3:15pm National Institutes of Health Tuesday, November 12, 2024 at 9:00 a.m. EST. Tuesday, November 12, 2024 at 3:00 p.m. EST. Both sessions will cover the same information. https://grants.nih.gov/grants/guide/notice-files/NOT-TW

High-End Instrumentation (HEI) Grant Program (S10 Clinical Trial Not Allowed) (PAR-24-264)

GRANT Friday, November 1, 2024- 3:30pm National Institutes of Health Applications will be accepted that request a single, commercially available instrument or an integrated instrumentation system. The minimum award is $750,001. There is no upper limit on the co

Tg12099 rat

RESEARCH MODELS Summary Tg12099 rats overexpress the 0N4R isoform of human tau with the P301S mutation linked to frontotemporal dementia. The MAPT transgene is driven by the rat Prnp promoter. Homozygous rats develop tau pathology, including neurofibrillary tangles, and

Shared Instrumentation Grant (SIG) Program (S10 Clinical Trial Not Allowed) (PAR-24-265)

GRANT Friday, November 1, 2024- 3:45pm National Institutes of Health Applications will be accepted that request a single, commercially available instrument or an integrated instrumentation system. The minimum award is $50,000. There is no upper limit on the cos

Biomedical Research Environment and Sponsored Programs Administration Development (BRE-SPAD) Program (UC2- Clinical Trial Not Allowed) (PAR-24-268)

GRANT Friday, November 1, 2024- 3:45pm National Institutes of Health Multiple due dates; see announcement. https://grants.nih.gov/grants/guide/pa-files/PAR-24-268.html 28 Jan 2027

Development of Biomarkers or Composite Biomarkers for Neurological and Neuromuscular Disorders (R61/R33- Clinical Trial Optional) (PAR-25-024)

GRANT Friday, November 1, 2024- 4:15pm National Institute of Neurological Disorders and Stroke Multiple due dates; see announcement. https://grants.nih.gov/grants/guide/pa-files/PAR-25-024.html 08 Jan 2028

Translational Neural Devices (R61/R33- Clinical Trial Optional) (PAR-25-053)

GRANT Friday, November 1, 2024- 4:30pm National Institute of Neurological Disorders and Stroke Multiple due dates; see announcement. https://grants.nih.gov/grants/guide/pa-files/PAR-25-053.html 29 Jan 2027

Pilot Projects Investigating Understudied Proteins Associated with Rare Diseases (R03 Clinical Trial Not Allowed) (PAR-25-122)

GRANT Friday, November 1, 2024- 4:30pm National Institutes of Health Application budgets are limited to $100,000 in direct costs (excluding subcontract F&A) for one year and need to reflect the actual needs of the proposed project. Multiple due dates; see a

NINDS Sustainable Transformation of Institutional Research Rigor (STIRR) Program (RC2- Clinical Trial Not Allowed) (RFA-NS-25-019)

GRANT Friday, November 1, 2024- 5:00pm National Institute of Neurological Disorders and Stroke Application budgets need to reflect the actual needs of the proposed project; however, it is anticipated that most awards will be between $150,000-$800,000 direct cos

PAPER Mao C, Dong L, Li J, Huang X, Lei D, Wang J, Chu S, Liu C, Peng B, Cui L, Gao J

Phenotype Heterogeneity and Genotype Correlation of MAPT Mutations in a Chinese PUMCH Cohort.

J Mol Neurosci. 2021 May;71(5):1015-1022. Epub 2020 Oct 1 PubMed.

PAPER Kim EJ, Kwon JC, Park KH, Park KW, Lee JH, Choi SH, Jeong JH, Kim BC, Yoon SJ, Yoon YC, Kim S, Park KC, Choi BO, Na DL, Ki CS, Kim SH

Clinical and genetic analysis of MAPT, GRN, and C9orf72 genes in Korean patients with frontotemporal dementia.

Neurobiol Aging. 2014 May;35(5):1213.e13-7. Epub 2013 Dec 4 PubMed.

PAPER Tang M, Gu X, Wei J, Jiao B, Zhou L, Zhou Y, Weng L, Yan X, Tang B, Xu J, Shen L

Analyses MAPT, GRN, and C9orf72 mutations in Chinese patients with frontotemporal dementia.

Neurobiol Aging. 2016 Oct;46:235.e11-5. Epub 2016 May 20 PubMed.

PAPER Li Y, Yang Z, Zhang Y, Liu F, Xu J, Meng Y, Xing G, Ruan X, Sun J, Zhang N

Genetic Screening of Patients with Sporadic Alzheimer's Disease and Frontotemporal Lobar Degeneration in the Chinese Population.

J Alzheimers Dis. 2024;99(2):577-593. PubMed.